Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma von Jansen, Y.J.L., Rozeman, E.A., Mason, R., Goldinger, S.M., Geukes Foppen, M.H., Hoejberg, L., Schmidt, H., van Thienen, J.V., Haanen, J.B.A.G., Tiainen, L., Svane, I.M., Mäkelä, S., Seremet, T., Arance, A., Dummer, R., Bastholt, L., Nyakas, M., Straume, O., Menzies, A.M., Long, G.V., Atkinson, V., Blank, C.U., Neyns, B.

Volltext

Tumor-infiltrating lymphocytes for the treatment of metastatic cancer von Geukes Foppen, M.H., Donia, M., Svane, I.M., Haanen, J.B.A.G.

Volltext

Vemurafenib for BRAF V600 mutated advanced melanoma: Results of treatment beyond progression von Scholtens, A, Geukes Foppen, M.H, Blank, C.U, van Thienen, J.V, van Tinteren, H, Haanen, J.B

Volltext

MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial von Rohaan, M.W., Gomez-Eerland, R., van den Berg, J.H., Geukes Foppen, M.H., van Zon, M., Raud, B., Jedema, I., Scheij, S., de Boer, R., Bakker, N.A.M., van den Broek, D., Pronk, L.M., Grijpink-Ongering, L.G., Sari, A., Kessels, R., van den Haak, M., Mallo, H.A., Karger, M., van de Wiel, B.A., Zuur, C.L., Duinkerken, C.W., Lalezari, F., van Thienen, J.V., Wilgenhof, S., Blank, C.U., Beijnen, J.H., Nuijen, B., Schumacher, T.N., Haanen, J.B.A.G.

Volltext

Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma von Geukes Foppen, M.H., Brandsma, D., Blank, C.U., van Thienen, J.V., Haanen, J.B., Boogerd, W.

Volltext

Phase 2 Study Comparing Pembrolizumab with Intermittent/short-term dual MAPK pathway inhibition plus Pembrolizumab(PEM) in patients harboring the BRAFV600 mutation (IMPemBra Trial) von Rozeman, E.A., Deken, M.A., Gadiot, J., Geukes Foppen, M.H., Pronk, L., Thienen, J.V., Haanen, J.B., Blank, C.U.

Volltext

Phase 2 Study Comparing Pembrolizumab with Intermittent/short-term dual MAPK pathway inhibition plus Pembrolizumab(PEM) in patients harboring the BRAFV600 mutation (IMPemBra Trial) von Rozeman, E.A., Deken, M.A., Gadiot, J., Geukes Foppen, M.H., Pronk, L., Thienen, J.V., Haanen, J.B., Blank, C.U.

Volltext

Randomized phase III study comparing a non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor infiltrating lymphocytes and interleukine-2 to s... von Rohaan, M.W., Borch, T.H., van den Berg, J.H., Geukes Foppen, M.H., Donia, M., Met, Ö, Nuijen, B., van Zon, M., Bakker, E.A.M., de Boer, R., Pronk, L.M., Wilgenhof, S., Blank, C.U., van Thienen, J.V., van Akkooi, A.C.J., Svane, I.-M., Haanen, J.B.A.G.

Volltext

Clinical aspects of immunotherapy and targeted therapy of advanced melanoma von Geukes Foppen, M.H.

Volltext bestellen